American Journal of Clinical Dermatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
This article reviews the current evidence about lebrikizumab in the management of AD. The phase II and phase III trials seem to corroborate efficacy of lebrikizumab in the treatment of moderate-to-severe AD, as shown by significant improvement of Eczema Area and Severity Index, body surface area, and pruritus scores. Also, lebrikizumab demonstrated favorable safety and tolerability profiles, with the majority of patients experiencing no significant adverse events. Lebrikizumab seems to be a promising emerging targeted biological agent for patients with moderate-to-severe AD. More data on the long-term efficacy and safety, ...
Source: American Journal of Clinical Dermatology - June 2, 2023 Category: Dermatology Source Type: research

Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
ConclusionsApremilast treatment demonstrated greater improvements in disease severity and patient-reported symptoms versus placebo at week 16 in Japanese patients with PPP with sustained improvements through week 32. No new safety signals were observed.ClinicalTrials.govNCT04057937. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 26, 2023 Category: Dermatology Source Type: research

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
ConclusionsAbrocitinib provided rapid and substantially greater improvements in skin clearance and quality of life compared with placebo and dupilumab in subgroups of patients with severe and/or difficult-to-treat AD. These findings support the use of abrocitinib for severe and/or difficult-to-treat AD.Trial registration:ClinicalTrials.gov, NCT03720470. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 22, 2023 Category: Dermatology Source Type: research

Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review
ConclusionNumerous targeted therapies have shown significant efficacy in improving nail findings in patients with psoriasis and psoriatic arthritis. Data from head-to-head trials have shown greater efficacy of ixekizumab over adalimumab and ustekinumab, as well as brodalumab over ustekinumab, while prior meta-analyses have demonstrated superiority of ixekizumab and tofacitinib to other included agents at various assessed timepoints. Further studies on the long-term efficacy and safety of these agents, as well as randomized controlled trials involving comparison with placebo arms, are needed to fully analyze differences in ...
Source: American Journal of Clinical Dermatology - May 20, 2023 Category: Dermatology Source Type: research

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
ConclusionThe safety profile for lebrikizumab consisted of TEAEs that were mostly nonserious, mild or moderate in severity, and did not lead to treatment discontinuation. The safety profile was similar in both adults and adolescents.Clinicaltrials.govNCT02465606, NCT02340234, NCT03443024, NCT04146363, NCT04178967, NCT04250337, NCT04250350, NCT04392154Video abstractSafety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials (MP4 34165 KB) (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 17, 2023 Category: Dermatology Source Type: research

Eosinophil –Lymphocyte Ratio, Eosinophil–Neutrophil Ratio, and Eosinophil–Monocyte Ratio in Chronic and Severe Urticaria
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 17, 2023 Category: Dermatology Source Type: research

Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 17, 2023 Category: Dermatology Source Type: research

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
ConclusionsCrisaborole QD was effective and well tolerated for long-term maintenance treatment and flare reduction in adult and pediatric patients with mild-to-moderate AD.Trial RegistrationClinicalTrials.gov, NCT04040192, 31 July 2019. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 15, 2023 Category: Dermatology Source Type: research

Automated Facial Acne Lesion Detecting and Counting Algorithm for Acne Severity Evaluation and Its Utility in Assisting Dermatologists
ConclusionsOverall, our algorithm demonstrated clinically applicable performance in detecting and counting facial acne lesions by type and its utility as an assistance tool for evaluating acne severity. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 9, 2023 Category: Dermatology Source Type: research

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management
AbstractAcute generalized exanthematous pustulosis (AGEP) is a rare, acute, severe cutaneous adverse reaction mainly attributed to drugs, although other triggers, including infections, vaccinations, ingestion of various substances, and spider bites, have also been described. AGEP is characterized by the development of edema and erythema followed by the eruption of multiple punctate, non-follicular, sterile pustules and subsequent desquamation. AGEP typically has a rapid onset and prompt resolution within a few weeks. The differential diagnoses for AGEP are broad and include infectious, inflammatory, and drug-induced etiolo...
Source: American Journal of Clinical Dermatology - May 8, 2023 Category: Dermatology Source Type: research

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy
ConclusionsResponse, according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, is, until now, the most important prognostic factor, and CR is a valid surrogate marker for long-term survival in patients treated with ICI. Our results highlight the importance of investigating the optimal therapy duration in complete responders.Graphical Abstract (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 4, 2023 Category: Dermatology Source Type: research

Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions
AbstractLupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs; keratinocytes, cytotoxic T cells and plasmacytoid dendritic cells (pDCs) establish a self-perpetuating interplay between the innate and adaptive immune system that is pivotal for t...
Source: American Journal of Clinical Dermatology - May 4, 2023 Category: Dermatology Source Type: research

Systemic Versus Topical Corticosteroids in the Treatment of DRESS: A Retrospective Cohort Study Followed by a Meta-Analysis
ConclusionsTopical corticosteroids may be a safe and efficacious alternative to systemic corticosteroids in the treatment of mild-to-moderate DRESS.Clinical Trial RegistrationPROSPERO registration CRD42021285691. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 3, 2023 Category: Dermatology Source Type: research